Tech Company Inital Public Offerings
Codiak BioSciences IPO
On 10/13/2020, Codiak BioSciences went public.
Transaction Overview
Company Name
Announced On
10/13/2020
Transaction Type
IPO
Amount
$82,500,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:[i] the advancement of exoSTING, including the conduct of our Phase 1/2 clinical trial;[ii] the advancement of exoIL-12, including the conduct of our Phase 1 clinical trial;[iii] the expansion of our engEx Platform, including to advance the research and development of our engEx discovery programs, and[iv] the remainder for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Technology Sq. 9th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Codiak Biosciences (Nasdaq: CDAK) is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Williams
Chief Financial Officer
Linda Bain
Vice President
Sriram Sathy
Vice President
Benny Sorensen
VP - Manufacturing
Konstantin Konstantinov
Browse more venture capital transactions:
Prev: 10/12/2020: goPuff venture capital transaction
Next: 10/13/2020: YotaScale venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs